PT1673472E - Utiliza??o de polimorfismos gen?ticos na predi??o de hepatotoxicidade induzida por f?rmacos - Google Patents
Utiliza??o de polimorfismos gen?ticos na predi??o de hepatotoxicidade induzida por f?rmacos Download PDFInfo
- Publication number
- PT1673472E PT1673472E PT04765830T PT04765830T PT1673472E PT 1673472 E PT1673472 E PT 1673472E PT 04765830 T PT04765830 T PT 04765830T PT 04765830 T PT04765830 T PT 04765830T PT 1673472 E PT1673472 E PT 1673472E
- Authority
- PT
- Portugal
- Prior art keywords
- genetic polymorphisms
- il1a
- hepatotoxicity
- predict drug
- induced hepatotoxicity
- Prior art date
Links
- 206010071602 Genetic polymorphism Diseases 0.000 title abstract 2
- 206010072268 Drug-induced liver injury Diseases 0.000 title 1
- 206010019851 Hepatotoxicity Diseases 0.000 abstract 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 abstract 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 abstract 2
- 230000007686 hepatotoxicity Effects 0.000 abstract 2
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract 1
- 101150097648 Il1a gene Proteins 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50897203P | 2003-10-06 | 2003-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1673472E true PT1673472E (pt) | 2011-05-12 |
Family
ID=34520003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04765830T PT1673472E (pt) | 2003-10-06 | 2004-10-05 | Utiliza??o de polimorfismos gen?ticos na predi??o de hepatotoxicidade induzida por f?rmacos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070248955A1 (enExample) |
| EP (1) | EP1673472B1 (enExample) |
| JP (1) | JP4979382B2 (enExample) |
| CN (1) | CN1882705A (enExample) |
| AT (1) | ATE498021T1 (enExample) |
| AU (1) | AU2004283234B2 (enExample) |
| BR (1) | BRPI0415299A (enExample) |
| CA (1) | CA2540760C (enExample) |
| DE (1) | DE602004031352D1 (enExample) |
| ES (1) | ES2361018T3 (enExample) |
| MX (1) | MXPA06003827A (enExample) |
| PL (1) | PL1673472T3 (enExample) |
| PT (1) | PT1673472E (enExample) |
| WO (1) | WO2005040415A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10262107B1 (en) * | 2013-03-15 | 2019-04-16 | Bao Tran | Pharmacogenetic drug interaction management system |
| CN108949947B (zh) * | 2017-05-25 | 2022-06-28 | 上海市预防医学研究院 | 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点 |
| CN116239665B (zh) * | 2023-03-10 | 2024-08-23 | 山东大学 | Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| WO2002030920A1 (en) * | 2000-10-12 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Benzimidazole compounds, process for producing the same and use thereof |
| GB0212648D0 (en) * | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
-
2004
- 2004-10-05 PL PL04765830T patent/PL1673472T3/pl unknown
- 2004-10-05 DE DE602004031352T patent/DE602004031352D1/de not_active Expired - Lifetime
- 2004-10-05 JP JP2006530097A patent/JP4979382B2/ja not_active Expired - Fee Related
- 2004-10-05 BR BRPI0415299-9A patent/BRPI0415299A/pt not_active Application Discontinuation
- 2004-10-05 MX MXPA06003827A patent/MXPA06003827A/es active IP Right Grant
- 2004-10-05 ES ES04765830T patent/ES2361018T3/es not_active Expired - Lifetime
- 2004-10-05 WO PCT/EP2004/011123 patent/WO2005040415A1/en not_active Ceased
- 2004-10-05 CN CNA2004800344189A patent/CN1882705A/zh active Pending
- 2004-10-05 EP EP04765830A patent/EP1673472B1/en not_active Expired - Lifetime
- 2004-10-05 US US10/574,768 patent/US20070248955A1/en not_active Abandoned
- 2004-10-05 AU AU2004283234A patent/AU2004283234B2/en not_active Ceased
- 2004-10-05 AT AT04765830T patent/ATE498021T1/de active
- 2004-10-05 CA CA2540760A patent/CA2540760C/en not_active Expired - Fee Related
- 2004-10-05 PT PT04765830T patent/PT1673472E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004283234B2 (en) | 2007-08-30 |
| US20070248955A1 (en) | 2007-10-25 |
| JP2007512231A (ja) | 2007-05-17 |
| AU2004283234A1 (en) | 2005-05-06 |
| ATE498021T1 (de) | 2011-02-15 |
| WO2005040415A1 (en) | 2005-05-06 |
| CA2540760C (en) | 2013-01-08 |
| ES2361018T3 (es) | 2011-06-13 |
| PL1673472T3 (pl) | 2011-07-29 |
| EP1673472A1 (en) | 2006-06-28 |
| MXPA06003827A (es) | 2006-06-14 |
| JP4979382B2 (ja) | 2012-07-18 |
| DE602004031352D1 (de) | 2011-03-24 |
| CA2540760A1 (en) | 2005-05-06 |
| BRPI0415299A (pt) | 2006-12-26 |
| EP1673472B1 (en) | 2011-02-09 |
| CN1882705A (zh) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301145I2 (nl) | Tirbanibulin | |
| TW200608961A (en) | Methods and reagents for the treatment of metabolic disorders | |
| ATE527385T1 (de) | Mit tumoren assoziierte genetische variationen | |
| EP1701941A4 (en) | COMPOUNDS FOR THE TREATMENT OF DISEASES WITH CELL PROLIFERATION | |
| AU2003285866A1 (en) | Methods for assessing efficacy of chemotherapeutic agents | |
| WO2006138275A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| EP1492440A4 (en) | NEW PROCEDURE FOR THE DIAGNOSIS AND FORECAST OF MALIGNES DISEASES | |
| EP2311984A8 (en) | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders | |
| EA200801046A1 (ru) | Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro | |
| MX2009013646A (es) | Metodos de diagnostico y tratamiento del cancer. | |
| MX2009008461A (es) | Variantes geneticas que contribuyen a riesgo de cancer de prostata. | |
| DE602005004461D1 (de) | Verfahren und Vorrichtung für das Verringern der Leistungsaufnahme von IRDA ermöglichten Handsets, indem ein IRDA Port dynamisch ein- und ausgeschaltet wird | |
| ATE527404T1 (de) | Waschmaschine, leitfähigkeitssensor in waschmaschine und steuerverfahren für waschmaschine | |
| MX2007007568A (es) | Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina. | |
| WO2007039290A3 (en) | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders | |
| UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
| TW200636075A (en) | Detection of nucleic acid variation by cleavage-amplification method | |
| SG158133A1 (en) | Method for reversing multiple resistance in animal cells | |
| DK1498129T3 (da) | Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling | |
| WO2008144599A3 (en) | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms | |
| WO2005034737A3 (en) | Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases | |
| MXPA05008793A (es) | Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. | |
| SI1730315T1 (sl) | Polimorfizmi v genu NOD2/CARD15 | |
| IL174195A0 (en) | Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes |